Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
The office building of the International Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bi -Bilateral Company.
Cfoto | Future Edition Gets the image
Astrazeneca On Monday, she said that by 2030 it plans to invest $ 50 billion to strengthen its production and scientific capabilities in the United States, becoming the latest pharmaceutical firm, which increased its public expenses in connection with the US trade tariffs.
Anglo-Swedish biotechnology company, which is with the headquarters in Cambridge, England, said that “cornerstone” commitments will be a new multi-billion dollar object for the production of weighing and metabolic portfolio, including the oral GLP-1 obesity tablet.
The planned Virginia Commonwealth facility should be the largest single Astrazenca investment in the world and “will use AI, automation and data analytics to optimize production,” the company said.
The latest funding will also expand the research and development and production of cell therapy in Maryland, Massachusetts, California, Indiana and Texas, and will create “tens of thousands of jobs,” Astrazeneca added.
The CEO Pascal Soriott said the commitment was at the heart of the “Faith Faith in Innovation in America” and support its ambitions to reach $ 80 billion in annual income by 2030, which is expected to come from the US from the US
Astrazeneca, which has created international headlines by developing one of the COVID-19 key vaccines, has long been prioritizing the US market. In the US, more than 40% of the company’s annual revenues in 2024.
In November, shortly after the US presidential election, Astrazeneca announced $ 3.5 billion in investments. Earlier this month, The Times reported that the firm could move its list from London to the US, what analysts said would be blow to the state markets of the UK.
Astrazeneca is the most valuable business indicated in the London FTSE 100. The company has refused to comment on the Times report.
Formal firms are increasing the costs on the US
Proclamation of Astrazenca Funding stems from similar steps of global pharmaceutical firms – including Novartis. Sanfi and Rosh and outdated in the US Eli Lily and Johnson and Johnson – Which in recent months has promised to increase their investment in the US amid US President Donald Trump’s demands to rethink domestic production.
The industry expects additional clarity in the pharmaceutical tariffs of the Trump administration, with the final result of section 232 in this sector paid at the end of this month. Effort Balanced US Drug Prices With those who are paid by other countries are also underway.
Trump at the beginning of this month suggested that the industry may face up to 200%With a short 12-18 months of graceful period to allow firms to move production states. However, many companies and analysts have called the terms insufficient.
“Usually, for most medicines, this is a three -time horizon. We work a lot to accelerate it as soon as possible, and demonstrate what we are doing the investment we have planned,” Novartis CEO said you last week during a profit call, adding that the administration will receive help.
